Ouster Digital Lidar Approved by Defense Department for Unmanned Aircraft
SAN FRANCISCO--(BUSINESS WIRE)-- Ouster, Inc. (Nasdaq: OUST) ('Ouster' or the 'Company'), a global leader in high-performance lidar sensors and intelligent software solutions, powering Physical AI across the automotive, industrial, robotics and smart infrastructure sectors, announced today that its OS1 digital lidar has been vetted and approved by the Department of Defense (DOD) for use in unmanned aerial systems (UAS).
Following a review of components and cybersecurity testing, the Defense Innovation Unit approved and added the Ouster OS1 to the Blue UAS Framework. Blue UAS is a holistic and continuous approach that rapidly vets and scales commercial UAS technology for the DOD. The Blue UAS Framework is an approved list of interoperable, National Defense Authorization Act (NDAA) compliant UAS components and software that provide options for government and industry partners. The Ouster OS1 is the first high-resolution 3D lidar sensor approved under the Blue UAS Framework and offers superior performance in weight, power efficiency, and reliability under rugged conditions compared to previously approved 2D lidar solutions.
'Ouster is committed to the responsible development of its products and has taken significant steps to secure its supply chain,' said Ouster CTO Mark Frichtl. 'As a result, our OS1 sensor was officially added to the Blue UAS list, providing drones and other UAS with access to industrial-grade, high-fidelity spatial awareness for advanced perception and autonomous operation. Ouster is proud to be the leading supplier of 3D lidar sensors for U.S. defense applications.'
Ouster's digital lidar sensors are compliant with the NDAA as affirmed by BlueUAS Framework, making them an ideal choice for applications where supply chain security is paramount. The Company's technology is already deployed in systems used by the United States Army, Navy, National Labs, NASA, and transportation departments, including in drones, ground vehicles, marine vessels, and traffic and security systems. Ouster takes steps to safeguard customer information, is committed to the security and responsible use of its products, and is ISO 27001 certified. Additionally, the Company offers Buy America(n) certified products, reflecting a commitment to domestic manufacturing and sourcing in the United States.
For more information on Blue UAS, visit: https://www.diu.mil/blue-uas.
About Ouster
Ouster (Nasdaq: OUST) is a global leader in high-performance lidar sensors and intelligent software solutions, powering Physical AI across the automotive, industrial, robotics, and smart infrastructure sectors. Ouster's technology delivers performance, reliability, and affordability to accelerate the adoption of autonomous systems at scale and drive meaningful improvements in safety, efficiency and sustainability. Ouster is headquartered in San Francisco, CA, with offices in the Americas, Europe, and Asia-Pacific. For more information about our products, visit www.ouster.com, contact our sales team, or connect with us on X or LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current plans, estimates and expectations of management that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as 'offer,' 'expect,' 'project,' 'intend,' 'believe,' 'may,' 'will,' 'should,' 'plan,' 'could,' 'continue,' 'target,' 'contemplate,' 'estimate,' 'forecast,' 'guidance,' 'predict,' 'possible,' 'potential,' 'pursue,' 'likely,' and the negative of these terms and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements, other than statements of historical fact, including statements regarding the capabilities and benefits of Ouster's products, including with respect to the mitigation of supply chain risks and their superiority and reliability under rugged conditions compared to 2D lidar solutions; Ouster's business objectives and plans, market growth, and competitive position, all constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including, but not limited to, risks related to Ouster's ability to respond to evolving regulations and standards; risks related to the adoption of its products, inaccurate forecasts of market growth, and supply chain constraints; and other important risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and updated by the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, once filed, and as may be further updated from time to time in the Company's other filings with the SEC. Readers are urged to consider these factors carefully and in the totality of the circumstances when evaluating these forward-looking statements, and not to place undue reliance on any of them. Any such forward-looking statements represent management's reasonable estimates and beliefs as of the date of this press release. While Ouster may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, other than as may be required by law, even if subsequent events cause its views to change.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
VeriSilicon Expands DSP Portfolio with Silicon-Proven ZSP5000 Vision Core Series for Edge Intelligence
SHANGHAI--(BUSINESS WIRE)--VeriSilicon ( today released the ZSP5000 Digital Signal Processing (DSP) series IPs, which are based on its fifth-generation silicon-proven DSP architecture. This product line adopts a highly scalable and energy-efficient design, and has been deeply optimized for compute-intensive workloads such as computer vision and embedded AI. Combined with the configurable nature of the architecture, this series of IP can provide excellent solutions with both energy and computing efficiency for various edge devices. With the growing adoption of OpenCV and the increasing demand for computer vision workloads alongside NPUs in edge intelligence computing, we are introducing the ZSP5000—our next-generation DSP IP series. Share The ZSP5000 series IPs include ZSP5000, ZSP5000UL, ZSP5000L, and ZSP5000H, delivering scalable vector processing performance ranging from 32 to 256 8-bit Multiply-Accumulate (MAC) operations per cycle. For even higher performance, VeriSilicon's multi-core ZSP5400H can combine multiple ZSP5000H cores in a multi-cluster architecture to further scale computing capability. The ZSP5000 series features a rich and intuitive instruction set optimized for ease of programming and efficient performance tuning, while its dedicated instructions accelerate common imaging and signal processing tasks such as vector-scalar arithmetic, horizontal reductions, permutations, shifts, table lookups, clamping, and averaging. It integrates the ZTurbo coprocessor interface, allowing customers to easily add custom instructions and hardware accelerators within the same pipeline, and is compatible with the OpenCV Application Programming Interface (API), ensuring seamless integration with the mainstream computer vision frameworks. Additionally, the ZSP5000 series is equipped with a full-featured memory subsystem, a multi-channel 3D DMA engine, and a scalable multicore configuration, supporting flexible deployment for a broad spectrum of applications. The ZSP5000 series IPs are backward compatible with VeriSilicon's scalar ZSPNano series, efficiently handling mixed MCU and DSP workloads. VeriSilicon also offers comprehensive ZView development tools, including an Eclipse-based Integrated Development Environment (IDE), cycle-accurate simulator, optimizing compiler, debugger, and profiling tools, streamlining software development and system integration. 'With the growing adoption of OpenCV and the increasing demand for computer vision workloads alongside NPUs in edge intelligence computing, we are introducing the ZSP5000—our next-generation DSP IP series. It supports the industry-standard OpenCV API, enables streamlined interfacing with NPUs via our FLEXA interface, and integrates built-in audio processing capabilities for multi-modal applications,' said Weijin Dai, Chief Strategy Officer, Executive Vice President, and General Manager of the IP Division at VeriSilicon. 'Energy efficiency is key at the edge, and the ZSP5000 series IPs feature an optimized memory access architecture to minimize processor power consumption. It also features ZTurbo, a custom instruction extension mechanism designed for targeted applications, which enables further power and performance optimization through seamless integration of hardware accelerators. Our leading customers are already leveraging these capabilities to achieve significant advancements in power and performance.' VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit:
Business Wire
an hour ago
- Business Wire
AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need
TOKYO--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.'s Yokohama Technical Center, marking the latest step in the global expansion of the company's Global Cell and Gene Technologies Division. The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available in three continents (Milan, Italy – Longmont, Colorado, U.S. – Yokohama, Japan). This new site precedes the opening of a new AGC Biologics Yokohama manufacturing facility on schedule to be operational in 2027 with pre-clinical through commercial services for mammalian-based protein biologics, cell therapies, and messenger RNA. The Yokohama location will provide process transfer and manufacturing services for pre-clinical and clinical trials to serve an expanding global cell therapy market. Its core technologies include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and CAR-T cell therapies. AGC Biologics Cell and Gene Technology Center of Excellence in Milan, with its nine product approvals by the EMA and FDA, hundreds of batches manufactured, and 30-year track record, will support and enable the successful ramp up of operation in the new Yokohama site. 'In a cell and gene therapy market of high volatility and witnessing consolidation of CDMOs, AGC Biologics is among the few experiencing significant growth and success. We are now building on this success to complete the vision of having a truly global offering,' said Luca Alberici, Executive Vice President of Global Cell and Gene Technologies at AGC Biologics. 'Now Asian developers can benefit from having a local supply within one of the best global infrastructures on the market for cell therapy. Moreover, customers can continue to leverage the offering of viral vector central supply in our Milan facility, which supplies around a third of the ex vivo gene therapy product approved for commercialization. AGC Biologics, through its proprietary ProntoLVV and BravoAAV platforms, aims to offer viral vectors at a sustainable cost for its clients targeting less than 1,000€ per CAR-T patient.' 'Our team of friendly experts in Milan have a strong reputation for collaboration and working side-by-side with customers to achieve clinical, late-phase, and commercial successes,' said Jun Takami, Senior Vice President and General Manager, Japan Region and Yokohama Facility. 'As part of this next major phase for cell therapy in the region, our Yokohama team is ready to support partners in accelerating drug development timelines while maintaining the highest quality standards in the industry." AGC Biologics is a part of AGC Inc.'s Life Science Company. The Life Science company operates over 10 facilities worldwide focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. The AGC Inc. Yokohama Technical Center, built in 2020, is dedicated to advancing AGC Inc.'s research and development capabilities in materials science, chemical processes, and biotechnology. Please visit to learn more about AGC Biologics' global network of services for protein biologics and cell and gene therapies. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide.
Yahoo
an hour ago
- Yahoo
Eureka Acquisition Corp Announces Revised Contribution to Trust Account and Terms and Conditions in Connection with Proposed Charter Amendment
New York, June 25, 2025 (GLOBE NEWSWIRE) -- Eureka Acquisition Corp (the 'Company') (Nasdaq: EURK), a blank check company, today announced that in connection with its previously announced extraordinary general meeting in lieu of an annual general meeting of shareholders to be held on June 30, 2025, at 9:00 a.m., Eastern Time (the 'Extraordinary General Meeting'), the Company has revised the contribution to its trust account and the terms and conditions in connection with the proposal to amend the Company's current Charter (the 'Charter Amendment Proposal'). The Charter Amendment Proposal provides that the Company has until July 3, 2025 to complete a business combination, and may elect to extend the period to consummate a business combination up to 12 times, each by an additional one-month extension (the 'Monthly Extension'), for a total of up to 12 months to July 3, 2026. In connection with the Charter Amendment Proposal, the revised terms and conditions (the 'Revised Terms'), among the others, include: If the Charter Amendment Proposal is approved, for each Monthly Extension, the amount of $150,000 shall be deposited into the trust account of the Company (the 'Revised Monthly Extension Fee') (as compared to the originally proposed amount as the lesser of (i) $60,000 for all remaining public shares and (ii) $0.03 for each remaining public share); The Company will file the Current Report on Form 8-K to disclose the deposit of each Revised Monthly Extension Fee timely; In the event that the Revised Monthly Extension Fee is not being deposited into the trust account by the 3rd day of each month since July 3, 2025, the Company has a period of thirty (30) days (the 'Cure Period') to pay any applicable past due payment for the Revised Monthly Extension Fee. If the Company fails to make any applicable past due payment during the Cure Period, then the Company shall immediately cease all operations, except for the purpose of winding up, and liquidate and dissolve with the same effect as if the Company failed to complete a business combination within the prescribed timeline; and The Company will not withdraw any amount out of the interest from the trust account to pay its dissolution expenses. The record date for determining the Company shareholders entitled to receive notice of and to vote at the Extraordinary General Meeting remains the close of business on May 23, 2025 (the 'Record Date'). Shareholders as of the Record Date can vote, even if they have subsequently sold their shares. Shareholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not to take any action. Shareholders who have not yet done so are encouraged to vote as soon as possible. There is no change to the location, the Record Date, or any of the other proposals to be acted upon at the Extraordinary General Meeting, except as otherwise provided herein. Shareholders who wish to withdraw their previously submitted redemption request may do so prior to the Extraordinary General Meeting by requesting that the Company's transfer agent return such shares by 5:00 p.m. Eastern Time on June 26, 2025. If you have questions regarding the certification of your position or delivery of your shares, please contact: Continental Stock Transfer & Trust Company1 State Street 30th FloorNew York, NY 10004-1561E-mail: spacredemptions@ The Company's shareholders who have questions regarding the Revised Terms, the Extraordinary General Meeting or would like to request documents may contact the Company's proxy solicitor, Advantage Proxy, Inc., at (877) 870-8565, or banks and brokers can call (206) 870-8565, or by email at ksmith@ About Eureka Acquisition Corp Eureka Acquisition Corp is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, incorporated for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as 'believes,' 'expects,' 'intends,' 'plans,' 'estimates,' 'assumes,' 'may,' 'should,' 'will,' 'seeks,' or other similar expressions. Such statements may include, but are not limited to, statements regarding the date of the Extraordinary General Meeting and the redemption request deadline. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements. Additional Information and Where to Find It On June 3, 2025, the Company filed a definitive proxy statement with the Securities and Exchange Commission (the 'SEC') in connection with its solicitation of proxies for the Extraordinary General Meeting. The Company will amend and supplement the definitive proxy statement to provide information about the Revised Terms and the Extraordinary General Meeting. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (including any amendments or supplements thereto) and other documents filed with the SEC through the web site maintained by the SEC at or by contacting the Company's proxy solicitor. Participants in the Solicitation The Company and its respective directors and officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Extraordinary General Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement. You may obtain free copies of these documents using the sources indicated above. Contact Information:Fen ZhangChairman and Chief Executive OfficerEmail: +86 135 0189 0555
